Quince Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 15 To Regain Compliance
SEC.
Stocks · News reference
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Quince Therapeutics, Inc. (QNCX)
Filed: 2026-09-04 AccNo: 0001193125-26-382838 Size: 140 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share